Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States
Wu, Jashin J., Patel, Manish, Zeng, Feng, Huang, Ahong, Pan, Xing, Cao, Yiwen, Chen, Naijun, Photowala, Huzefa, Garg, Vishvas, Crowley, Jeff
Published in The Journal of dermatological treatment (31.12.2023)
Published in The Journal of dermatological treatment (31.12.2023)
Get full text
Journal Article
The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel
Burshtein, Joshua, Shah, Milaan, Zakria, Danny, Lockshin, Benjamin, Crowley, Jeff, Merola, Joseph F., Gordon, Ken, Shahriari, Mona, Korman, Neil J., Chovatiya, Raj, Kalb, Robert, Lebwohl, Mark
Published in Dermatology and therapy (01.02.2024)
Published in Dermatology and therapy (01.02.2024)
Get full text
Journal Article
Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized, double-blinded, active-controlled, comparative clinical study over 52 weeks
Blauvelt, Andrew, Papp, Kim, Trivedi, Mona, Barragan, Carolina, Chow, Vincent, Mytych, Daniel T, Yamauchi, Paul, Crowley, Jeff, Franklin, Janet
Published in British journal of dermatology (1951) (23.10.2024)
Published in British journal of dermatology (1951) (23.10.2024)
Get full text
Journal Article
Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy: 5-Year Safety From VOYAGE (VOY)1&2
Blauvelt, Andrew, Thaci, Diamant, Papp, Kim, Ho, Vincent, Ghoreschi, Kamran, Kim, Byung Soo, Miller, Megan, Shen, Yaung-Kaung, You, Yin, Yu, Jenny, Yang, Ya-Wen, Crowley, Jeffrey, Foley, Peter
Published in Skin (Milwood, N.Y.) (04.03.2022)
Published in Skin (Milwood, N.Y.) (04.03.2022)
Get full text
Journal Article